The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Hang Quach, MBBS, MD, FRACP, FRCPA
Advertisement
Articles by Hang Quach, MBBS, MD, FRACP, FRCPA
Advertisement
Latest Updated Articles
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple MyelomaPublished: June 2nd 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
3
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
4
Collagen Implant May Improve Local Control of Metastatic Brain Tumors
5
